Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...

SEATTLE – February 17, 2026 – Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein-Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is ...

In the fight against common childhood illnesses, scientists have turned to an unusual source: the blood of paediatricians. It turns out this is a treasure trove of powerful antibodies that could be ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria. A novel class of antibodies that binds to a ...

Antibodies are the immune system's precision tools for recognizing and neutralizing viruses, bacteria and other foreign substances that can make us ill. These proteins circulate in the bloodstream and ...

Antibodies touch nearly every corner of healthcare. These carefully crafted proteins can target cancer cells, control autoimmune diseases, fight infections, and destroy the toxic proteins that drive ...

One day, probably in the next year or two, a company will claim it has put the first artificial-intelligence-designed antibody in the clinic. But the industry is divided on what “AI-designed” really ...

I don’t know about you, but I’ve always preferred making my own antibodies. Why outsource it? It’s so handy letting my own body do the work of fighting infections while I’m writing articles or ...

A specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving polycystic kidney disease. Early mouse studies suggest it may halt or even ...

Image of antibodies created from scratch. (UW Institute for Protein Design / Ian C. Haydon Graphic) Researchers from Nobel Laureate David Baker’s lab and the University of Washington’s Institute for ...

The antibody drug market value is expected to reach $445 billion in the next five years, with over 160 antibodies currently licensed globally for a wide breadth of conditions, including cancer, ...